Clinical-stage developer of small molecule targeted cancer therapies
Shenzhen TargetRx is a clinical-stage drug developer pursuing small molecule targeted therapies for treatment-resistant cancers. Its stack pairs computational discovery tools (PyTorch, TensorFlow, XGBoost, HPC, cryo-EM, UniProt) with clinical data standards (SAS, CDISC) and SAP S/4HANA alongside SAP R/3. Hiring is accelerating and senior-weighted, with job posts centered on procurement, BOM cost control and digital factory work, which points to a buildout of manufacturing and supply operations.
Shenzhen TargetRx, Inc. is a privately held pharmaceutical R&D company founded in 2014 and headquartered in Shenzhen, Guangdong, China. It develops targeted oncology drugs aimed at patients whose cancers no longer respond to existing treatments. The company runs in-house small molecule discovery platforms that cover drug design, screening, evaluation and optimization. It holds a patent portfolio spanning China, the US, Europe and Japan, and several compounds are in multinational clinical trials. The company employs 51–200 people.
TargetRx uses SAP S/4HANA, AWS, Azure, GCP, Kubernetes, Terraform and Python. For R&D and clinical work it runs PyTorch, TensorFlow, XGBoost, HPC, cryo-EM, LC-MS, SAS and CDISC.
Yes. Hiring is accelerating and skews toward senior roles, mainly in engineering and operations. There are also openings in sales, manufacturing, security and product, all based in China.
TargetRx is headquartered in Shenzhen, Guangdong, China. It was founded in 2014 and has 51–200 employees.
Other companies in the same industry, closest in size
Shenzhen TargetRx, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.